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a  b  s  t  r  a  c  t
There  are  many  new  advances  in  neuroscience  and  mental  health  which  should  lead  to  a  greater  under-
standing  of  the neurobiological  dysfunction  in neuropsychiatric  disorders  and  new  developments  for
early,  effective  treatments.  To do this,  a biomarker  approach  combining  genetic,  neuroimaging,  cogni-
tive  and  other  biological  measures  is  needed.  The  aim  of  this  article  is  to  highlight  novel approaches  for
pharmacological  and  non-pharmacological  treatment  development.  This  article  suggests  approaches  that
can  be  taken  in  the  future  including  novel  mechanisms  with  preliminary  clinical  validation  to provide
a  toolbox  for  mechanistic  studies  and also  examples  of  translation  and  back-translation.  The  review
also  emphasizes  the need  for clinician-scientists  to be  trained  in a novel  way  in order  to equip  them
with  the  conceptual  and  experimental  techniques  required,  and  emphasizes  the  need  for  private-public
partnership  and  pre-competitive  knowledge  exchange.  This  should  lead  the  way  for important  new  holis-
tic  treatment  developments  to improve  cognition,  functional  outcome  and  well-being  of  people  with
neuropsychiatric  disorders. [TD.CR.ABS]
[TD.CR.ABS.P]© 2013  Elsevier  Ltd.  
The last decade has witnessed exciting and important advances
in the neuroscience of mental health including the mapping of
neural circuitry and neurochemical mechanisms, identiﬁcation of
multiple genetic loci and the application of novel technologies
to both the pathophysiology and treatment of mental disorders.
Despite these advances, major unmet needs remain. Mental illness
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remains the leading cause of morbidity and mortality (Bloom
et al., 2011; Collins et al., 2011; Insel, 2009). Psychiatric conditions
account for ﬁve of the top ten causes of disability and premature
death and mental health conditions are the leading cause of Dis-
ability Adjusted Life Years accounting globally for 37% of healthy
life years lost from Non-Communicable Diseases. The global cost
for disorders of mental health in 2010 was $2.5 trillion and pro-
jected to markedly increase to $6.5 trillion in 2030, making mental
illness the most costly form of chronic disease worldwide (Bloom
et al., 2011). Furthermore, a considerable proportion of people
with mental health problems remain untreated. For example, in
the USA 67% and in Europe 74% of people with mental illness are
untreated. (Thornicroft, 2007) Yet, in spite of these urgent unmet
needs, mental health is experiencing a crisis in the development
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of new treatments, especially drug treatments. In the last 40 years,
very few therapeutics with novel mechanisms have progressed to
phase III clinical trials or regulatory approval. Major pharmaceutical
companies are even shifting drug discovery efforts away from psy-
chiatric toward non-psychiatric disorders with identiﬁed biological
targets (Cressey, 2010; Miller, 2010). This issue of private sector
drug development is one major symptom reﬂecting deeper under-
lying infrastructural issues in mental health research. The Royal
Society recently convened an International Scientiﬁc Seminar to
ﬁnd innovative solutions for novel drug development. The meeting
concluded that to address these issues, we require a paradigm shift
in how we: diagnose and categorize psychiatric disorders, view and
approach mental health research, encourage collaborative partner-
ship models between academia and drug companies, train the next
generation of clinicians, maintain the pre-clinical knowledge base
and inﬂuence the public perception of mental illness. The following
seeks to address these fundamental problems and to propose a way
forward for the next two decades.
1. Many psychiatric disorders are neurodevelopmental in
origin
Psychiatric disorders are brain disorders of complex and vari-
able genetic risk interacting with neural circuitry and experience.
Mental disorders disproportionately affect the young with 75% of
illnesses having onset before the age of 24 (Kessler et al., 2005).
The identiﬁcation of multiple genetic loci for complex disorders
exploded in the decade following the sequencing of the ﬁrst human
genome, with 2850 disease genes identiﬁed for Mendelian-based
disorders and 1100 loci identiﬁed for 165 common multigenic dis-
eases as of February, 2011 (Lander, 2011). Accordingly, in the most
heritable neuropsychiatric disorders (autism, schizophrenia, bipo-
lar disorder) at least a dozen risk alleles have been reported from
genome wide association studies, including many common vari-
ants replicated recently in a global effort with over 100,000 subjects
across 65 research institutions (Fig. 1) (Ripke et al., 2011; Sklar et al.,
2011). Supporting the concept of mental disorders as neurodevel-
opmental, several of these apparent risk loci are key factors in neu-
rodevelopmental pathways. In addition to the genomic evidence,
longitudinal imaging studies have demonstrated altered patterns of
development in patients with mental disorders. For instance, chil-
dren with attention deﬁcit hyperactivity disorder show a profound
and consistent delay in cortical maturation (Shaw et al., 2007).
These kinds of ﬁndings have led to a reconceptualization of mental
disorders as brain disorders resulting from the aberrant develop-
ment of speciﬁc circuits. This reconceptualization is exempliﬁed in
a new model of major depression which proposes different nodes
for the underlying circuits, with alterations in neural pathways
for emotion, cognition, interoception, and self-awareness (Drevets
et al., 1997; Ressler and Mayberg, 2007). These pathways not only
suggest a new stratiﬁcation for depression, they may  provide dif-
ferential targets for medications, cognitive behavioral therapy, and
deep brain stimulation. (Drevets and Furey, 2010; Holtzheimer and
Mayberg, 2011; Zarate et al., 2006) Initiatives such as The Human
Connectome Project (www.humanconnectomeproject.org) and
the 1000 Connectomes Project (www.fcon 1000.projects.nitrc.org)
which are mapping the variation in whole brain structural and
functional network organization through large scale data sharing
schemes should yield a consensus wiring diagram of the human
brain and a range of individual variation, analogous to the maps of
common and uncommon variation in the human genome.
1.1. Challenges in drug development
Despite these major advances in knowledge, progress in the
search for novel therapeutic compounds has been difﬁcult. Several
inter-related  factors account for this failure. Thus far, genetics has
not uncovered druggable targets for mental disorders. The many
variants identiﬁed have conspicuously not revealed targets related
to monoamines, suggesting that genetics may  take us beyond the
cluster of current drugs, but we will need to bridge the gap between
genetic ﬁndings and targets. An additional challenge is that the
disease state remains based on phenomenological rather than bio-
logical categories, with limited understanding of pathophysiology.
Additionally, there is a need for breakthrough clinical insights.
The development of an antihistaminergic compound into chlorpro-
mazine as an antipsychotic and imipramine as an antidepressant
in the 1950s was a major novel development that revolutionized
treatment in psychiatry. While we  are likely to dismiss these dis-
coveries in mental health as the result of serendipity and careful
observation rather than anchored in established rational mecha-
nistic processes, there is no reason to assume that careful clinical
insights will not yield important therapeutic innovations in the
future. Nevertheless, without a clear understanding of the biolog-
ical basis of a disorder it will certainly be more difﬁcult to ﬁnd a
rational approach to novel treatments. An example of hypothesis-
driven drug development was that of the cholinesterase inhibitors
in treating cognitive symptoms in dementias. This development
was based on a pathological hypothesis derived from neuropathol-
ogy and clinical analysis with utilization of existing pharmacolog-
ical tools to validate the target. The result is a class of compounds
particularly useful in improving attention and concentration, in
patients with mild to moderate Alzheimer’s disease (Eagger et al.,
1991) but clearly more effective treatments are required particu-
larly for episodic memory symptoms and neuroprotection.
A constellation of factors including the absence of molecu-
lar targets for drug discovery, the increasing cost and average
duration of treatment discovery, and increasing placebo response
rate and failure rates in clinical trials has led us to this crisis in
drug development. (Nutt and Goodwin, 2011) Due to these chal-
lenges, a wealth of compounds interacting with promising targets
have been developed by drug companies but lack convincing evi-
dence of efﬁcacy and are generally not available for widespread
research by academic investigators. At the same time that we are
facing a profound unmet need for new treatments and unprece-
dented scientiﬁc progress, research and development in industry
is moving elsewhere, risking a lost generation for new treatment
development.
1.2. Novel approaches for drug development
How can we address these fundamental issues? Our goals and
perspective of mental health must change. Understanding molecu-
lar mechanisms will allow the identiﬁcation of novel therapeutic
targets including that of circuitry, genomics and epigenomics.
Genetic ﬁndings in psychiatry, especially highly penetrant genetic
lesions, need to advance to deﬁne new molecular targets. Unlike
other ﬁelds where tissue biopsies or tumor removal has routinely
been used to study pathophysiology and create cellular models of
disease for testing new therapeutics, in psychiatric disorders brain
tissue is rarely available during life. Functional and structural imag-
ing, electrophysiology, and blood and cerebrospinal ﬂuid-based
measurements might yield glimpses into underlying pathological
processes, especially when applied longitudinally during the years
of risk and prodromal stages. Recently, the advent of skin-derived
stem cells, also known as induced pluripotent cells (iPSc), that can
be converted into neurons and glia in vitro promises to unveil
pathogenetic mechanisms. (Tobe et al., 2011) Not only will iPScs
create a “disease in a dish”, these individualized cultures can serve
as substrates for high throughput screening and testing novel thera-
peutics. Indeed, early results using iPSc’s in genetically determined
neurological disorders such as Rett’s syndrome, Parkinson’s disease
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Fig. 1. Complex genetics of mental disorders: prevalence and risk. This ﬁgure outlines genetic risk factors and rare genetic aetiologies that may  be appropriate for population
based screening and translation into therapeutic approaches. Three categories are identiﬁed: highly penetrant or high risk but rarely identiﬁed; more commonly identiﬁed
through genomic sequencing; and higher prevalence but low contribution to risk. The degrees of penetrance are deﬁned as follows: highly penetrant (the trait or symptom
will almost always be expressed in those carrying the allele); incomplete or reduced (some individuals fail to express the trait despite carrying the allele); low penetrance
(an allele will only sometimes produce the symptom).
(LRRK2-linked) and Spinal muscular atrophy has conﬁrmed that
such cultures can mimic  known cellular defects faithfully, raising
hopes for neurodevelopmental conditions like schizophrenia with
more complex etiologies. (Brennand et al., 2011)
How can we progress from genetic signals to molecular tar-
gets? In other ﬁelds, genetics is beginning to yield new targets. For
example, BCL11A is a new target for drug development in sickle cell
anemia. In people with a common variant that decreases expression
of BCL 11A, a transcriptional repressor, fetal hemoglobin pro-
duction is not repressed during development allowing enhanced
oxygen carrying capacity even in those with the sickle cell muta-
tion of adult hemoglobin. Thus, the blockade of this repressor of
fetal hemoglobin represents a potentially novel therapeutic target.
(Sankaran et al., 2008) Identifying such molecular mechanisms in
mental disorders is crucial to the development of new biological
targets. But if mental disorders are like other medical disorders,
we may  need to look for variants that are protective, where loss
of function reduces risk. Furthermore, in addition to the complex
technical issues of molecular targeting, it will need to address safety
issues.
We need new approaches to identify risk factors or prodro-
mal signs early enough in the course of illness to intervene before
a disorder becomes a disability. Neurocognitive assessments and
neuroimaging have already been applied to the identiﬁcation of
the prodrome of schizophrenia and early phases of autism. Genet-
ics could also inform risk, even before the prodrome. While we  are
not ready for genetic screening for one of the many common risk
alleles in neonates or young children, the detection of rare vari-
ants that are highly penetrant may  already be clinically useful in
some settings. These approaches suggest a transformation of diag-
nosis that considers risk states as well as symptomatic phases of
the illness, as adopted in cardiology and oncology. Clearly, we  need
predictive biomarkers to identify an individual’s vulnerability and
resilience and provide markers for personalized and targeted ther-
apies. And importantly, treatments for these high risk states are
likely to be psychosocial (family support, cognitive training) rather
than biomedical. There will of course be important ethical issues
associated  with potential stigma, the risk of false positives and
other consequences of genetic screening.
In addition to considering the opportunities for treatment of
prodromal and possibly high risk states, a new approach to symp-
tomatic disorders could yield innovative ways of approaching
treatment development (Sahakian et al., 2010). The Diagnostic
and Statistical Manual for Mental Disorders is currently for clin-
ical and research use. The Research Domain Criteria (RDoC) is
a new effort that focuses on dimensions that cut across dis-
ease categories focusing on core domains of functioning that map
on to clinical neural circuits and genetics as well as preclini-
cal studies of brain and behavior (Insel et al., 2010; Sanislow
et al., 2010). The RDoC is currently used as a research tool
which may  identify new clinical targets, such as anhedonia
or social deﬁcits, that can become new therapeutic endpoints.
In the future, with further understanding of the underlying
neurobiology and pathophysiologically relevant processes in ani-
mals and humans, the RDoC approach may  well be for clinical
use.
Beyond identifying new molecular targets and new clinical
targets, we need to expect more of the next generation of ther-
apeutics. Our treatment targets have been focused too much on
symptom relief and too little on recovery; too much on treating the
late stages of illness and too little on pre-emptive therapies during
the prodromal stage (Beddington et al., 2008; Collins et al., 2011;
Sahakian et al., 2010). For recovery, treatment needs to consider
compliance, which remains a pervasive problem with current med-
ications. To decrease morbidity and mortality, treatments need to
be embedded in comprehensive medical care with supports for
social and occupational function. And rather than a single magic
bullet, our therapeutic targets should shift toward combination
and integrative therapies which can combine pharmacologi-
cal, psychosocial therapies and neurotechnologies. The use of
d-cycloserine and CBT for phobias exempliﬁes such an effective
combination therapy (Ressler et al., 2004). Other novel techniques
and applications of new technology include the use of training
through video games which may  enhance cognitive performance
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in the prodromal stage of schizophrenia or increase eye contact
in children with autism (Sahakian, 2011; Sahakian et al., 2010).
Similarly, the rapid response of major depression to ketamine
along with the identiﬁcation of biomarkers of response emphasizes
the promise of novel therapeutics (Diazgranados et al., 2010).
In  addition to changing what we do, we should consider changes
in how we develop the next generation of therapeutics. Innova-
tive, collaborative partnerships are already being forged between
academia and industry, recognizing that the old models are not
going to be sufﬁcient for future success. The development of a novel
opioid receptor inverse agonist for overeating provides an effec-
tive example of a novel risk/reward sharing partnership between
academia and a private sector partner (Rabiner et al., 2011).
A  ‘fast-fail’ approach should be emphasized but must be
balanced with comprehensive and thorough proﬁling across
disease dimensions with adequate statistical power to dispel
doubt. Greater communication and exchange of knowledge
between academic and industry researchers will allow a shar-
ing of existing and even new compounds. Joint development
of validated methodology and infrastructure is likely to lead
more quickly to new drug registrations and is more suited to
current business models. There is an unprecedented increase
in willingness of companies to engage in data and compound
sharing, as exempliﬁed by the European Union/European
Federation of Pharmaceutical Industries and Associations
Innovative Medicines Initiative (www.imi.europa.eu) and the
European  College of Neuropsychopharmacology medicine chest.
(www.ecnp.eu/projects-initiatives/ECNP-medicines-chest.aspx)
Arch2POCM is a new effort engaging several industry and academic
scientists in a new paradigm for neuroscience drug development,
redeﬁning precompetitive space to enhance sharing, including
translational models, data and samples.
Paradoxically, the reduction in Pharma investment in central
nervous system disorders could be a boon for academic scientists.
Compounds in industry that are not currently actively investigated
could be made available for further non-clinical investigation, and if
safe and fully qualiﬁed for clinical studies, should be made available
for further mechanistic studies. There may  now be fewer imped-
iments to ‘repurposing’ and ‘rescue’. These approaches leverage
existing investment and knowledge leading potentially to a lower
risk and faster return. From a patient’s perspective, focusing on
mechanisms underlying side effect burden in chronic treatments
in order to retain efﬁcacy but improve acceptability and wellbeing
would be a major advance leading to greater compliance and there-
fore reduced costs.
Experimental medicine approaches are not new, however and
repeating the best efforts of company-directed clinical trials via
academic or academic-industrial consortia is unlikely to be game-
changing without including a new strategy. Pharmacokinetic,
toxicological and biomarker optimization for novel compounds and
targets is the strength of the pharmaceutical industry. Predicting
the potential beneﬁcial effects of compounds from preclinical pro-
ﬁling methods that have translational predictive validity is neither
a current strength of the industry nor of academia and is arguably
the key reason why the late stage drug development pipeline is
dry. We  need to consider animal disease models and functional
assays in as much a new way as we do clinical investigation follow-
ing the removal of the constraints of classical psychiatric disease
diagnosis: animal models of schizophrenia will never recapitulate
all the disease symptoms but the biological dimensions of arousal,
reward, motivation and cognition and the circuitries that under-
lie them can be accessed in animals now more easily than ever
before and can be used to identify molecular control points – as
well as chemical ligands that can modulate them. A paradigmatic
example of successful translation and back-translation focusing on
a  core cognitive dimension is described in Fig. 2. This approach
to  addressing effective translation underlies the Cognitive Neuro-
science Treatment Research to Improve Cognition in Schizophrenia
(CNTRICS) initiative (Carter et al., 2008). The job of experimental
medicine then becomes one of focussing the clinical investigation
of the chemical ligands, or hopefully medicines, across these same
dimensions in a systematic way  in both volunteers and in patients.
Experimental medicine thus needs to consider ways of quantita-
tively phenotyping patients and those at high-risk along these same
dimensions with both clinical and preclinical scientists harnessing
novel biomarker technologies (functional and structural imaging,
connectivity, electrophysiology, cognitive paradigms, serological
and immunological markers and (epi)genomics) in order to maxi-
mize convergent validity.
Funding  agencies such as the Wellcome Trust and Medical
Research Council have recently been targeting the deﬁciencies
in drug development by providing funding for target validation,
developing candidate therapeutic agents and Proof of Concept
trials. Awards are targeted at collaborations between academia
and industry. Recent funding schemes focus on promoting exper-
imental medicine and increasing research capacity and training
through the support of multi-disciplinary research groups, enhanc-
ing research training and adding incentive for research careers in
mental health research. Support for the development of respos-
itories of large scale datasets and data sharing encourages the
development of population health data. In the United States, the
National Institutes of Health (NIH) has proposed the formation of a
new institute, the National Center for Advancing Translational Sci-
ence (NCATS), speciﬁcally to support research on the discipline of
translation, identifying and overcoming roadblocks to the develop-
ment of new treatments.
To  bring this vision forward, the training of a new cadre of
clinician scientists is a necessary foundation. (Bullmore et al.,
2009; Lehner and Insel, 2010) The NIH Neuroscience Blueprint
has announced grants targeting neuroscience education prior to
entering university, emphasizing neuroscience training at an early
stage. Training programs in psychiatry should focus on integrating
basic and clinical neuroscience, translational medicine and novel
methodologies. These principles are incorporated into the One
Mind project (www.1Mind4Research.org). It is also vital that the
institutional knowledge built up in industry and academic drug dis-
covery teams is not lost. Knowledge manifest in key individuals in
industry may  need to be protected by encouraging re-employment
of key individuals in academic posts.
The public perception of mental health and pharmaceutical
research is crucial to the support of this vision. The role of govern-
ment should be to work together with interest groups, including
patient advocacy groups, to facilitate rapid development in trans-
lation into practice of novel, safe and effective treatments. As
with other areas of medicine, these treatments may be optimized
by targeting at speciﬁc subgroups, identiﬁed through biomarkers
and endophenotypes. Private-public partnerships working closely
with patient groups and government could greatly improve pub-
lic access for speciﬁc groups of patients to effective treatments for
speciﬁc symptoms. Financial incentives for innovation are required
along with addressing legislation to protect brand, know-how and
patents.
The Royal Society Seminar addressing these challenges in drug
development resulted in a series of initiatives: The Institute of
Medicine (USA) will facilitate meetings to develop the infrastruc-
ture to place drugs in a publically accessible space – a ‘medicine
cabinet’ – and investigate legal issues surrounding intellectual
property rights and insurance. Here we  outline a series of novel
mechanisms with preclinical validity in psychiatric disorders with
high potential for further development by industry (Table 1). The
table provides some examples which highlight the bi-directional
communication necessary for a successful academia-industry
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Fig. 2. Translation and back-translation: cognitive ﬂexibility. Intra-dimensional and extra-dimensional (ID/ED) set shifting tasks assess reversal learning (response to shift in
outcome  contingency) and attentional set-shifting (response to shift in focus of attention within the same dimension (IDS) or a different dimension (EDS)). (A-C) Translational
studies: Dissociation of reversal learning and extra-dimensional set shifting as a function of prefrontal cortical sectors has been demonstrated in 4 species: (A) human; (B)
marmoset; (C) rat and (not illustrated) mouse. Graphs for the marmoset and rat show the number of trials to criterion for ID, ED and Reversal learning in control (white),
orbitofrontal cortex (red) and rodent medial prefrontal cortex and marmoset lateral prefrontal cortex (green). Graph for human shows fMRI units for Reversal and EDS in
orbitofrontal cortex (red) and ventrolateral prefrontal cortex (green). These images are adapted from (Brown and Bowman, 2002; Dias et al., 1997; Hampshire and Owen,
2006). (D) The graph shows the improvement in EDS (*p < 0.05) when patients with schizophrenia are given modafanil (yellow) versus placebo. This graph is adapted from
Turner  et al. (2004). (E) Back-translation: In rats, PCP (black) worsens EDS compared to vehicle (white). This deﬁcit is ameliorated by modafanil (yellow). The effects of
sertindole, risperidone and haloperidol are also shown. This graph is adapted from (Goetghebeur and Dias, 2009).
partnership and will enhance knowledge of and access to the
compounds that may  be eligible for ‘repurposing’ and ‘rescue’,
although they may  not have been successful for their initial clinical
indication.
Neuroscience is well poised for high impact discoveries,
which have real possibilities to improve functional outcome and
wellbeing of patients with mental health problems. It should
be  possible to have a vision of a holistic treatment for these
debilitating psychiatric disorders that will signiﬁcantly beneﬁt
patient outcome, as well as the economy. The issue of drug discov-
ery underscores infrastructure issues in mental health research.
Whilst some of these issues are being aggressively addressed and
were recently highlighted (Insel and Sahakian, 2012), much more
needs to be done. The aim of this paper is to provide a focus as
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Table 1
Novel mechanisms with preliminary clinical validation: examples for a toolbox for mechanistic studies.
Class Mechanism Indication References
Glutamate based therapies NMDA antagonists (ketamine like) Major depressive disorder (Zarate et al., 2010)
NMDA NR2b blockers Major depressive disorder (Preskorn et al., 2008)
Metabotropic glutamate agonists
(mGluR2-3)
Schizophrenia (Patil et al., 2007)
Glycine transport (GlyT1) blockers Schizophrenia—negative symptoms (Pinard et al., 2010)
Modulation  of other Neurotransmitters Serotonin-6 (5HT6) blockers Cognitive symptoms in depression and
schizophrenia
(Maher-Edwards et al., 2010)
Alpha7-nicotinic agonists Cognitive symptoms in AD and
schizophrenia
(Tregellas et al., 2011)
Histamine-3 Cognition and ADHD (Schwartz, 2011)
Muscarinic (M1) agonists Cognitive symptoms in AD and
schizophrenia
(Bodick et al., 1997)
GABA A alpha 2,3 selective agonists Anxiety, schizophrenia (Lewis et al., 2008)
Triple reuptake inhibitor (5HT, NE, DA Major depressive disorder (Tran et al., 2011)
to how to progress discussion toward achieving this obtainable
vision over the next two decades.
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